Thiopurine methyltransferase alleles in British and Ghanaian populations

Thiopurine methyltransferase (TPMT) catalyses the S-methylation of thiopurine drugs such as 6-mercapto-purine, 6-thioguanine and azathioprine. TPMT activity is inherited as an autosomal co-dominant trait, and several mutations in the TPMT gene have been identified which correlate with a low activity phenotype. Although ethnic differences in TPMT activity have been described, population frequency analysis of TPMT alleles has not been well defined in different ethnic groups. The frequency of four allelic variants of the TPMT gene, TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C were compared in British Caucasian (n = 199) and Ghanaian (n = 217) populations using PCR-RFLP and allele- specific PCR-based assays. TPMT*3C was found in 14.8% of Ghanaians (31 heterozygotes, one homozygote). The TPMT*2, TPMT*3A and TPMT*3B alleles were not detected in any of the Ghanaian samples analysed. In contrast, 10.1% of British subjects had variant alleles, consisting of TPMT*2 (n = 2), TPMT*3A (n = 17) and TPMT*3C (n = 1) alleles. The frequencies of mutant alleles in this study were 5.3 and 7.6% in British Caucasians and Ghanaians, respectively. Among Ghanaian tribes, Ewe subjects had a lower frequency of mutant alleles (5.9%) than Ga (13.2%) or Fanti (11.6%), although this did not reach statistical significance. This study provides the first analysis of TPMT mutant allele frequency in an African population and indicates that, unlike Caucasians, TPMT*3C is the most common allele in African subjects.      

Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons

To understand the functional significance and mechanisms of action in the CNS of endogenous and exogenous cannabinoids, it is crucial to identify the neural elements that serve as the structural substrate of these actions. We used a recently developed antibody against the CB1 cannabinoid receptor to study this question in hippocampal networks. Interneurons with features typical of basket cells showed a selective, intense staining for CB1 in all hippocampal subfields and layers. Most of them (85.6%) contained cholecystokinin (CCK), which corresponded to 96.9% of all CCK-positive interneurons, whereas only 4.6% of the parvalbumin (PV)-containing basket cells expressed CB1. Accordingly, electron microscopy revealed that CB1-immunoreactive axon terminals of CCK-containing basket cells surrounded the somata and proximal dendrites of pyramidal neurons, whereas PV-positive basket cell terminals in similar locations were negative for CB1. The synthetic cannabinoid agonist WIN 55,212-2 (0.01-3 microM) reduced dose-dependently the electrical field stimulation-induced [3H]GABA release from superfused hippocampal slices, with an EC50 value of 0. 041 microM. Inhibition of GABA release by WIN 55,212-2 was not mediated by inhibition of glutamatergic transmission because the WIN 55,212-2 effect was not reduced by the glutamate blockers AP5 and CNQX. In contrast, the CB1 cannabinoid receptor antagonist SR 141716A (1 microM) prevented this effect, whereas by itself it did not change the outflow of [3H]GABA. These results suggest that cannabinoid-mediated modulation of hippocampal interneuron networks operate largely via presynaptic receptors on CCK-immunoreactive basket cell terminals. Reduction of GABA release from these terminals is the likely mechanism by which both endogenous and exogenous CB1 ligands interfere with hippocampal network oscillations and associated cognitive functions.     

Kinetics of neovascularisation of splenic autotransplants in mice

The aim of this study was to examine the kinetics of neovascularisation of splenic autoimplants into the abdominal cavity after splenectomy in mice. Sixty-eight female Swiss mice were submitted to splenectomy. The spleen from each animal was sliced and the slices were implanted into the abdominal cavity. Groups of animals were killed after 1, 2, 3, 5, 7, 15, 21, 28, 42, 56, 70 and 84 d. Fluorescent polystyrene microspheres were injected via the orbital venous plexus before killing and the splenules were removed 5 min later for light and electron microscopy. Mesenteric blood vessels were injected with coloured latex to study the origin of the nutrient vessels. Three days after the implant the microspheres were observed at the periphery and then migrating to the internal parts of the implant in the subsequent days. The blood supply to the implants originated from branches of the splenic, short gastric, mesenteric and gastroepiploic arteries. It is concluded that revascularisation of splenic autografts proceeds centripetally, starting as early as 3 d after implantation.     

Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis

Women with osteoporosis treated for 36 months with twice‐yearly injections of denosumab sustained fewer hip fractures compared with placebo. Treatment might improve femoral bone at locations where fractures typically occur. To test this hypothesis, we used 3D cortical bone mapping of postmenopausal women with osteoporosis to investigate the timing and precise location of denosumab versus placebo effects in the hips. We analyzed clinical computed tomography scans from 80 female participants in FREEDOM, a randomized trial, wherein half of the study participants received subcutaneous denosumab 60 mg twice yearly and the others received placebo. Cortical 3D bone thickness maps of both hips were created from scans at baseline, 12, 24, and 36 months. Cortical mass surface density maps were also created for each visit. After registration of each bone to an average femur shape model followed by statistical parametric mapping, we visualized and quantified statistically significant treatment effects. The technique allowed us to pinpoint systematic differences between denosumab and control and to display the results on a 3D average femur model. Denosumab treatment led to an increase in femoral cortical mass surface density and thickness, already evident by the third injection (12 months). Overall, treatment with denosumab increased femoral cortical mass surface density by 5.4% over 3 years. One‐third of the increase came from increasing cortical density, and two‐thirds from increasing cortical thickness, relative to placebo. After 36 months, cortical mass surface density and thickness had increased by up to 12% at key locations such as the lateral femoral trochanter versus placebo. Most of the femoral cortex displayed a statistically significant relative difference by 36 months. Osteoporotic cortical bone responds rapidly to denosumab therapy, particularly in the hip trochanteric region. This mechanism may be involved in the robust decrease in hip fractures observed in denosumab‐treated women at increased risk of fracture. © 2014 American Society for Bone and Mineral Research.     

Improved Survival and Reduced Phenotypic Severity Following AAV9/MECP2 Gene Transfer to Neonatal and Juvenile Male Mecp2 Knockout Mice

Typical Rett syndrome (RTT) is a pediatric disorder caused by loss-of-function mutations in the methyl-CpG binding protein 2 (MECP2) gene. The demonstrated reversibility of RTT-like phenotypes in mice suggests that MECP2 gene replacement is a potential therapeutic option in patients. We report improvements in survival and phenotypic severity in Mecp2-null male mice after neonatal intracranial delivery of a single-stranded (ss) AAV9/chicken β-actin (CBA)-MECP2 vector. Median survival was 16.6 weeks for MECP2-treated versus 9.3 weeks for green fluorescent protein (GFP)-treated mice. ssAAV9/CBA-MECP2–treated mice also showed significant improvement in the phenotype severity score, in locomotor function, and in exploratory activity, as well as a normalization of neuronal nuclear volume in transduced cells. Wild-type (WT) mice receiving neonatal injections of the same ssAAV9/CBA-MECP2 vector did not show any significant deficits, suggesting a tolerance for modest MeCP2 overexpression. To test a MECP2 gene replacement approach in a manner more relevant for human translation, a self-complementary (sc) adeno-associated virus (AAV) vector designed to drive MeCP2 expression from a fragment of the Mecp2 promoter was injected intravenously (IV) into juvenile (4–5 weeks old) Mecp2-null mice. While the brain transduction efficiency in juvenile mice was low (~2–4% of neurons), modest improvements in survival were still observed. These results support the concept of MECP2 gene therapy for RTT.     

Cardiac transplantations in dogs: evaluation with MR

To assess the potential of magnetic resonance (MR) imaging as an early predictor of cardiac transplant rejection, electrocardiogram-gated (ECG-gated) MR imaging was performed in 12 dogs with heterotopic cardiac transplants. Twenty-two examinations were performed in vivo, and ten postmortem examinations were performed immediately after the dogs were killed. Examinations were performed from 3 days to 14 weeks after transplantation. A 0.35-T superconducting magnet was used with the spin-echo pulse sequence. There was a significant increase (P less than .02 to P less than .001) in T2 relaxation times and intensity values for the transplanted hearts compared with native hearts at all time intervals after transplantation. T1 relaxation times of native and transplanted hearts showed no significant difference on the in vivo ECG-gated studies. However, T1 values calculated on post-mortem studies were significantly longer (P less than .005) in the transplanted compared with the native hearts. With longer pulse repetition and echo delay times, there was an increase in the contrast between the rejecting transplanted heart and the native heart. Thus, ECG-gated MR imaging using the spin-echo technique displays cardiac allograft rejection in vivo. The rejected myocardium in vivo is characterized by a prolonged T2 relaxation time.     

Vascular β-Adrenoceptor-mediated Relaxation and the Tone of the Tissue in Canine Arteries

The aim of the present investigation was to study the influence of the tone in the response to β-adrenoceptor activation of four different canine arteries: coronary, pulmonary, mesenteric and splenic. Five different levels of tone were produced (of about 35, 50, 65, 80 and 95% of the maximum) by adding phenylephrine (0·6, 1·0, 2·0, 4·0, and 10 μm , respectively) to the bath. In the coronary artery at spontaneous tone, low concentrations of noradrenaline or adrenaline (1–3 nm ) caused either relaxation or contraction, while after induced tone, both noradrenaline and adrenaline caused concentration-dependent relaxations, noradrenaline being more potent (EC50 of 0·16 (0·13–0·20) and 0·38 (0·28–0·67) μm , respectively; n = 6; P < 0·05). Only in the coronary artery did isoprenaline relax the tissue irrespective of the previous level of tone. In all the other arteries, isoprenaline was able to cause concentration-dependent relaxations only if the previous tone was submaximal. At 80% of the maximum, isoprenaline caused relaxation in the mesenteric and pulmonary arteries, but in the splenic artery it caused relaxation only when the tone was of about 65% of the maximum or less. While in the coronary artery atenolol and ICI-118,551 (erythro-dl 1(7-methylindan-4-yloxy)-3-isopropylaminobutan-2-ol) were equipotent in antagonizing isoprenaline, noradrenaline and adrenaline, in the other vessels ICI-118,551 was from 58 (splenic artery) to 525 (mesenteric artery) times more potent than atenolol against the isoprenaline relaxant effect. We conclude that: the tone of the vessel represents a critical factor deciding the sense of the response (coronary artery; low concentrations of noradrenaline or adrenaline), the level at which the relaxant effect is triggered (mesenteric = 80% vs splenic = 65%), and the magnitude of the relaxant effect (always). β-Adrenoceptors predominate in the mesenteric, pulmonary and splenic arteries, while β₁-adrenoceptors predominate in the coronary artery. It is unlikely that adrenaline is able to cause vasodilation in any of the vascular beds studied.     

Complement C6 and C2 Biosynthesis in Syngeneic PVG/c− and PVG/c+ Rat Strains

A PVG rat strain with total deficiency of C6 and partial deficiency of C2 (PVG/c⁻), and a syngeneic control strain (PVG/c⁺), were used to study the production of extrahepatically synthesized complement. Livers of complement deficient rats were transplanted in sufficient rats (Tx−L). The C6 and C2 levels in Tx−L rats declined within 2 days to 25% and 30%, respectively, and remained stable for more than 6 weeks. To investigate the contribution of C6 synthesis by the liver, C6 sufficient livers were grafted in deficient rats (Tx+l). After an initial increase, with maximum C6 levels of 119% at 10 days following transplantation, the C6 levels decreased gradually and C6 was no longer detectable 28 days after transplantation. This decline in C6 levels was dependent on antibody production against C6. No significant change in the C3, C4, factor H and factor B levels was observed. Expression of C6 mRNA in the grafted PVG/c⁺ sufficient liver was comparable to the expression of C6 mRNA in control PVG/c⁺ livers while C6 mRNA expression in the transplanted PVG/c⁻ liver and the control PVG/c⁻ liver was lower. In conclusion, it was demonstrated in vivo that not only C6 but also C2 is synthesized extrahepatically in PVG/c rats.